Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
- Income Statement
- Statement of Comprehensive Income
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Geographic Areas
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Dividend Discount Model (DDM)
- Return on Equity (ROE) since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Current Enterprise Value (EV)
Current share price (P) | |
No. shares of common stock outstanding | |
US$ in thousands | |
Common equity (market value)1 | |
Add: Preferred Stock, par value $.01 per share; issued and outstanding: none (per books) | |
Total equity | |
Add: Finance lease liabilities, current portion (per books) | |
Add: Long-term debt (per books) | |
Add: Finance lease liabilities, excluding current portion (per books) | |
Total equity and debt | |
Less: Cash and cash equivalents | |
Less: Marketable securities | |
Enterprise value (EV) |
Based on: 10-K (reporting date: 2023-12-31).
1 Common equity (market value) = Share price × No. shares of common stock outstanding
= ×
Historical Enterprise Value (EV)
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 Data adjusted for splits and stock dividends.
2 Closing price as at the filing date of Regeneron Pharmaceuticals Inc. Annual Report.
3 2023 Calculation
Common equity (market value) = Share price × No. shares of common stock outstanding
= ×
Item | Description | The company |
---|---|---|
EV | Enterprise value is total company value (the market value of common equity, debt, and preferred equity) minus the value of cash and short-term investments. | Regeneron Pharmaceuticals Inc. EV increased from 2021 to 2022 and from 2022 to 2023. |